ATXG vs REGN · $3.7M cap vs P/E 14, rev $4.29B
Addentax Group Corp (ATXG) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Addentax Group Corp (ATXG) is a integrated freight & logistics company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
Latest reported ATXG revenue for 2026-03-31 was $0. Net income was -$4.5M. Revenue was down 100.0% from 2025-03-31 to 2026-03-31. ATXG currently screens at market cap $3.7M.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
ATXG currently screens at market cap $3.7M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the ATXG and REGN stock pages for the full models.
Not investment advice.